

Anti-TNF- α (Golimumab), Human IgG1 Antibody

06/20

CATALOG NO.: A2141-100 (100 μ g)

BACKGROUND DESCRIPTION: Golimumab is a human IgG1 kappa monoclonal antibody derived from HuMab transgenic mice immunized with human tumor necrosis factor alpha (TNF- α). This antibody targets and neutralizes soluble as well as transmembrane human TNF- α , which plays a key role in chronic inflammatory diseases such as Rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, Psoriatic arthritis, and ankylosing spondylitis. Golimumab was developed by Janssen Biotech and received FDA approval in 2009 for the treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and ankylosing spondylitis (AS). Additionally, in 2013, this antibody received approval for the treatment of ulcerative colitis. Golimumab is marketed under the trade name SIMPONI®.

ALTERNATE NAMES: CNTO 148, CNTO-148, Simponi ARIA, Simponi, TNFSF2, TNF-alpha, TNFA, TNF- α , TNF α

ANTIBODY TYPE: Monoclonal

CONCENTRATION: 1 mg/ml

HOST/ISOTYPE: Recombinant / IgG1, kappa

SOURCE: CHO cells

IMMUNOGEN: Golimumab

MOLECULAR WEIGHT: 146.9 kDa

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-IL-6 receptor (Tocilizumab), Human IgG1 Antibody (A1447)

Anti-IL-6R α (Sarilumab), Human IgG1 Antibody (A2133)

Anti-TNF alpha (Infliximab), Human IgG1 Antibody (A1097)

Anti-TNF alpha (Humicade), Human IgG4 Antibody (A1093)

Anti-VEGF (Bevacizumab), humanized Antibody (A1045)

FOR RESEARCH USE ONLY! Not to be used on humans.